# Coherus BioSciences

Source: https://onco.cc/companies/coherus/  
OnCo record `coherus` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Coherus is a Californian company that grew up on biosimilars and now holds the US rights to toripalimab, the anti-PD-1 antibody approved in 2023 for nasopharyngeal carcinoma, the first FDA approval for that cancer.

## Summary

Coherus BioSciences, based in Redwood City, California, built its business on biosimilars of pegfilgrastim and other biologics before refocusing on oncology. It licensed the anti-PD-1 antibody toripalimab from Junshi Biosciences for the United States and Canada and won FDA approval in October 2023 for recurrent or metastatic nasopharyngeal carcinoma with chemotherapy, the first drug approved in the United States for that disease. The company is developing toripalimab combinations and other immuno-oncology candidates. Company facts are from the official website and FDA approval records.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Coherus BioSciences, Inc.; Coherus Oncology
- Tags: fda-oce-applicant
- HQ: Redwood City, CA
- Type: biotech
- Website: https://www.coherus.com/

## Sources

- Official website: https://www.coherus.com/
- FDA: oncology and hematologic malignancies approval notifications: https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- drugs: [Toripalimab](https://onco.cc/drugs/toripalimab/)
- trials: [Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC](https://onco.cc/trials/nct07281716/), [Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer](https://onco.cc/trials/nct07140679/), [JUPITER-02](https://onco.cc/trials/jupiter-02/), [Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases](https://onco.cc/trials/nct07277322/), [STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas](https://onco.cc/trials/nct06975293/)

---
JSON: https://onco.cc/api/v1/entities/coherus.json